- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06852053
Application to Predict Neonatal Apnea With Bradycardia (APNeA)
Application to Predict Neonatal Apnea With Bradycardia (APNeA Study)
This purpose of this study is to reduce or stop apneas and bradycardias in pre-term infants, before they occur using gentle stimulation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a randomized cross-over trial that will use additional ECG leads connected to a novel device and laptop to determine the accuracy and efficacy of an algorithm to predict, detect, and interrupt episodes of bradycardia for two 4-hour periods. There will be a 4-hour period without vibro-tactile stimulation and a 4-hour period with vibro-tactile stimulation when episodes are predicted or detected.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rachel L. Benz, Clinical Research Nurse Manager, MSN
- Phone Number: 205-934-2184
- Email: rlbenz@uabmc.edu
Study Contact Backup
- Name: Kimberly M. Armstead Clinical Research Coordinator III, B.S.
- Phone Number: 205-934-0095
- Email: karmstead@uabmc.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Recruiting
- University of Alabama at Birmingham
-
Contact:
- Kimberly M. Armstead Clinical Research Coordinator III, B.S.
- Phone Number: 205-934-0095
- Email: karmstead@uabmc.edu
-
Contact:
- Rachel L Benz Clinical Research Nurse Manager, MSN
- Phone Number: 205-934-2184
- Email: rlbenz@uabmc.edu
-
Principal Investigator:
- Colm P. Travers, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented episodes of apnea with bradycardia over the previous 24 hours.
- Off ventilatory support/NCPAP for > 48 hours prior to study entry
- Gestational age < 32 0/7 weeks' gestation at birth
- Parents/legal guardians have provided consent for enrollment
Exclusion Criteria:
- a major malformation or a neuromuscular condition that affects respiration or causes apnea, or terminal illness or decision to withhold or limit support.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Virbrotactile stimulation
Four hours of vibrotactile stimulation via a closed loop device if an apnea or bradycardia episode is predicted or detected. |
Vibro-Tactile stimulation when bradycardia is predicted or predicted. |
|
Sham Comparator: Control
Four hours of no vibrotactile stimulation via the closed loop device if an apnea or bradycardia episode is predicted or detected. |
Sham closed-loop vibrotactile stimulator |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bradycardia <100 beats per minute ≥ 10 seconds
Time Frame: 4-hours on either intervention.
|
The frequency of episodes of bradycardia (heart rate less than 100 of ≥ 10 seconds) in either study arm during the study period. |
4-hours on either intervention.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bradycardia <60 beats per minute ≥ 5 seconds
Time Frame: 4 hours in either intervention.
|
The frequency of episodes of bradycardia (heart rate <60 beats per minute ≥ 5 seconds) in either study arm during the study period. |
4 hours in either intervention.
|
|
Bradycardia <60 beats per minute ≥ 10 seconds
Time Frame: 4 hours on either intervention.
|
The frequency of episodes of bradycardia (heart rate <60 beats per minute ≥ 10 seconds) in either study arm during the study period. |
4 hours on either intervention.
|
|
Bradycardia <80 beats per minute ≥ 5 seconds
Time Frame: 4 hours on either intervention.
|
The frequency of episodes of bradycardia (heart rate <80 beats per minute ≥ 5 seconds) in either study arm during the study period. |
4 hours on either intervention.
|
|
Bradycardia <80 beats per minute ≥ 10 seconds
Time Frame: 4 hours on either intervention.
|
The frequency of episodes of bradycardia (heart rate <80 beats per minute ≥ 10 seconds) in either study arm during the study period. |
4 hours on either intervention.
|
|
Proportion of time with Bradycardia < 100 beats per minute
Time Frame: 4 hours on either intervention.
|
The total proportion of time with bradycardia during the study period on either intervention with a heartrate of <100 beats per minute. |
4 hours on either intervention.
|
|
Hypoxemia <85% for ≥ 5 seconds
Time Frame: 4 hours on either intervention.
|
The frequency of episodes of hypoxemia (oxygen saturations <85% for ≥ 5 seconds) in either study arm during the study period. |
4 hours on either intervention.
|
|
Hypoxemia <85% for ≥ 10 seconds
Time Frame: 4 hours on either intervention.
|
The frequency of episodes of hypoxemia (oxygen saturations <85% for ≥ 10 seconds) in either study arm during the study period. |
4 hours on either intervention.
|
|
Hypoxemia <90% for ≥ 5 seconds
Time Frame: 4 hours on either intervention.
|
The frequency of episodes of hypoxemia (oxygen saturations <90% for ≥ 5 seconds) in either study arm during the study period. |
4 hours on either intervention.
|
|
Hypoxemia <90% for ≥ 10 seconds
Time Frame: 4 hours on either intervention.
|
The frequency of episodes of hypoxemia (oxygen saturations <90% for ≥ 10 seconds) in either study arm during the study period. |
4 hours on either intervention.
|
|
Hypoxemia <80% for ≥ 5 seconds
Time Frame: 4 hours on either intervention.
|
The frequency of episodes of hypoxemia (oxygen saturations <80% for ≥ 5 seconds) in either study arm during the study period. |
4 hours on either intervention.
|
|
Hypoxemia <80% for ≥ 10 seconds
Time Frame: 4 hours on either intervention.
|
The frequency of episodes of hypoxemia (oxygen saturations <80% for ≥ 10 seconds) in either study arm during the study period. |
4 hours on either intervention.
|
|
Proportion of time with hypoxemia < 90%
Time Frame: 4 hours on either intervention.
|
The total proportion of time with oxygen saturations <90% during the study period on either intervention. |
4 hours on either intervention.
|
|
Bradycardia prediction time
Time Frame: 4 hours on either intervention.
|
The number of seconds ahead of routine patient monitors at which the device algorithm predicted bradycardia in either group. |
4 hours on either intervention.
|
|
Bradycardia prediction accuracy
Time Frame: 4 hours on sham control.
|
The area under the curve for the true prediction rate over the false alarm rate in the control group. |
4 hours on sham control.
|
|
Proportion of time with hypoxemia < 85%
Time Frame: 4 hours on either intervention.
|
The total proportion of time with oxygen saturations <85% during the study period on either intervention. |
4 hours on either intervention.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Colm P. Travers Associate Professor of Pediatrics, M.D., University of Alabama at Birmingham
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 300008477
- UAB (Other Identifier: UAB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Deidentified individual participant data will be made available upon publication through a data use agreement to researchers who provide a methodologically sound proposal for use in achieving the goals of the approved proposal. Proposals should be submitted to cptravers@uabmc.edu.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.